Skip to content
StockMarketAgent
Direct answer
argenx is a premier hyper-growth biotech firm transitioning to a commercial powerhouse. Its lead asset, VYVGART, is rapidly becoming the standard of care in generalized Myasthenia Gravis (gMG) and is successfully expanding into CIDP. The 'pipeline-in-a-product' strategy provides a long-duration growth profile with multiple multi-billion dollar indication opportunities. Fair value range: low $654, high $2709, with mid-point at $1486.
Stock analysis

ARGX fair value $654–$2,709

By StockMarketAgent.AI team· supervised by
Analyzed: 2026-05-20Next update: 2026-08-20Methodology v2.4Data cut-off: Quality gate: passSources: all material sources passed deterministic freshness/provenance gatesReview: automatedArchetype: Hyper-growth
View archive
Last price
$797.77
▲ +688.71 (+86.33%)
Fair value
$1486
$654–$2709
Rating
Strong Buy
confidence 82/100
Upside
+86.3%
upside to fair value
Margin of Safety
$1263.51
MoS level · 15%
Market Cap
$49.9B
P/E fwd 21.8

§1 Executive summary

  • Commercial-stage status with visible traction in gMG/CIDP provides a reliable valuation floor.
  • Robust pipeline diversity reduces binary outcome risk compared to single-asset biotechs.
  • Forward earnings captures the massive earnings reset expected as assets reach peak penetration.
Fair value
$1,486
Margin of safety
+46.3%
Confidence
82/100
Moat
6.5/10

Educational analysis only — not financial advice. Always do your own due diligence.

$797.77Price
Low $654.18
Mid $1,486.48
High $2,709.48

argenx is a premier hyper-growth biotech firm transitioning to a commercial powerhouse. Its lead asset, VYVGART, is rapidly becoming the standard of care in generalized Myasthenia Gravis (gMG) and is successfully expanding into CIDP. The 'pipeline-in-a-product' strategy provides a long-duration growth profile with multiple multi-billion dollar indication opportunities.

  • IP-protected antibody platform
    IP-protected antibody platform
  • Pipeline-in-a-product strategy
    Pipeline-in-a-product strategy
  • Cycle upside
    High demand for specialized autoimmune therapeutic platforms.

§2 Bear case

In a sustained high-cost environment where CIDP expansion falters, valuation relies entirely on established gMG revenues.

Ways this thesis can break

FcRn Class Competition

· Medium

Next-generation competitors outcompete on pricing or efficacy, eroding market share.

FV impact
Severe

Secondary Indication Failures

· Low

Regulatory delays or clinical failures across 3+ secondary indications cap revenue.

FV impact
Moderate

Margin Compression

· Medium

Failure to cross 15% operating margins by FY2027 due to sustained high SG&A.

FV impact
Moderate
Early-warning signals to monitor
MetricCurrentTrigger threshold
Operating margins failing to cross 15% by FY2027.MonitorDeterioration versus the report thesis
Regulatory rejection in secondary indications.MonitorDeterioration versus the report thesis
Clinical failure across more than 3 secondary indications.MonitorDeterioration versus the report thesis
Loss of market share in gMG to competitors.MonitorDeterioration versus the report thesis
Sustained increase in SG&A without revenue growth.MonitorDeterioration versus the report thesis

§3 Financial history

Income statement — last six periods
Line itemT−0T−1T−2T−3CAGR
Period2022-12-312023-12-312024-12-312025-12-31Trend
Revenue$410.7M$1.23B$2.19B$4.15B+116.2%
Gross profit$381.3M$1.11B$1.96B$3.70B+113.3%
Operating income$-723.9M$-420.6M$-17.8M$1.05B—
Net income$-709.6M$-295.1M$833.0M$1.29B—
EPS (diluted)$-13.05$-5.16$12.78$19.57—
EBITDA$-622.8M$-192.3M$105.2M$1.31B—
R&D$663.4M$859.5M$983.4M$1.36B+27.2%
SG&A$469.9M$709.5M$1.05B$1.36B+42.5%

Quality scores

OCF / Net income
0.53×
>1 indicates high earnings quality
Accounting quality gate
Fail
Sector-adjusted gate
ROIC
13.8%
Return on invested capital
§3

Numbers analysis

Cash flow

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

Capital allocation

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

Individual subscribers — §4 onwards11 more sections

Read the full analysis — 11 more sections.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Full report for every covered ticker
24 months of rating archive
Watchlist briefings + rating-change alerts
PDF + DOCX export in any language
Start free trial
Cancel anytime.
MARGINS FAQ

ARGX margins questions

  1. ARGX (ARGX)'s margin set covers gross margin, operating margin, net margin, and free-cash-flow margin. The five-year trajectory is plotted so the reader can separate cyclical noise from secular trend.

FAQ

ARGX — frequently asked questions

  1. Based on our latest analysis, ARGX looks meaningfully undervalued. The current price is $798 versus a composite fair-value midpoint of $1486 (range $654–$2709), which implies roughly 86.3% upside to the midpoint.

Related coverage

Names readers of ARGX also follow

Same archetype: hyper-growth